![Establishing An Academic Career: A Discussion With Neal S Kleiman](https://assets.radcliffecardiology.com/s3fs-public/podcast/2024-03/EP_01_15.png?VersionId=AjkwIfp379rmsVAPQnW0kWu8OyrKirUk)
14: Establishing An Academic Career: A Discussion With Neal S Kleiman
Recorded on site at TCT, COAPT investigator Dr Neal Kleiman and Ankur discuss the realities of establishing an academic career as an interventional cardiologist. Neal explains why it is important to wear multiple hats and balance academia with a clinical presence.
Digging more into the practicalities of everyday work-life, Neal reflects on the challenges of reporting to multiple bosses who have different goals, and how geography enabled him to move between cathlab and academia. Neal also shares what he looks for in early career academic cardiologists. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read MoreRead Less
![Gregg W Stone On Becoming A Clinician, Trialist And Educator](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Gregg-Stone.png?VersionId=NwUGNesFk0N2olrrGu1n7604yjFTPuSb&itok=VCHU_wQv)
How did Gregg from Cleveland, Ohio become Gregg W Stone MD, world-leading interventional cardiologist and clinical trialist? This week, Ankur had the pleasure of speaking to Gregg about his personal and professional journey through the ‘golden years’ of interventional cardiology.
Gregg also shares his tips on how to progress from clinical practice to academic research, and what it takes to be a successful clinical investigator. Finally, Gregg shares with Ankur what personality traits he looks for in mentees and why presenting a final project is not enough. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Gregg also shares his tips on how to progress from clinical practice to academic research, and what it takes to be a successful clinical investigator. Finally, Gregg shares with Ankur what personality traits he looks for in mentees and why presenting a final project is not enough. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
All Episodes
![Drug-Coated Balloons Small-Vessel CAD Brilakis - Megaly](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Brilakis-and-Megaly.png?VersionId=5e3JcL291o0RS5trUH3gXO6gawEByNsF&itok=wne5Gva2)
Listen to our first episode with two guests! Ankur spoke with Emmanouil S Brilakis, MD and Michael Megaly, MD from the Minneapolis Heart Institute, Abbott Northwestern Hospital about their article on the role of drug-coated balloons in small-vessel coronary artery disease (SVD) published in US Cardiology Review 13.1. Percutaneous coronary intervention of SVD remains challenging due to difficulties with device delivery and high restenosis rate, making drug-coated balloons an attractive emerging option in patients with SVD.
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
Read More
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
![04: J Dawn Abbott On Recent Developments In Percutaneous Coronary Intervention](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-J-Dawn-Abbot.png?VersionId=or7p.TA7ztGjeOTgC8mLKMLM0BtmWa0.&itok=b5t4ZU5g)
We have observed a lot of developments in percutaneous coronary intervention (PCI) over the past 12 months with the publication of various studies and trials. This week, Ankur spoke with J. Dawn Abbott, MD, Associate Professor of Cardiology at Warren Medical School of Brown University about her recently published US Cardiology Review 13.1 article on the significant developments in PCI over the past 12 months.
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![03: Athena Poppas On Effective Management Of Hypertension](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Athena-%20Poppas_2.png?VersionId=h4WiM05z59aZvdzCLsJoSMvMD.whcm47&itok=_85zPXJC)
This week’s podcast guest needs no introduction! Prof Athena Poppas is one of the most widely known cardiologists in the US and current Vice-President of the American College of Cardiology! Ankur spoke to Athena about her recently published US Cardiology Review 13.1 article on whether early management of hypertension by GPs can improve outcomes.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![High-Sensitivity Cardiac Troponin ACS](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/Parallax-Podcast-w-Athena-%20Poppas_0.png?VersionId=uAw7s0xUwfjE1_1xcLbM7odh7YHQJw7K&itok=pSrlvyyg)
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
![01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-03/Parallax_01_1200x628.jpg?VersionId=8YtGXyCvpISHGUAWuUfXgEArl7M4TInv&itok=fTCIJSke)
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
![EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1| recent cardiology trials](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/1920x1080_PP_EP60.png?VersionId=5RD29a41Ka6RNtdDgzazifTh_tnmcFut&itok=vkisLegl)
In the last Parallax episode of the year, Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.
Read More
![Parallax AHA Edition: 3 Trials that will change your practice with Dr Amit Khera](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/EP59_PP_1920x1080_Web_Thumbnail.png?VersionId=R.EhdsJ426kSouiUM7QobjhJoBxYBRuk&itok=x73s1klk)
In this AHA 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr Amit Khera, Professor and Director of Preventive Cardiology at UT Southwestern Medical Center, Dallas and Vice Chair of the Scientific Sessions. For this week’s show, Dr Khera selected three thought-provoking late-breaking trials that will inform or change clinical practice.
Read More
![Parallax TCT Edition: 3 Trials that will Change Your Practice with Prof Mamas Mamas](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/PP_EP58_1920x1080_Web_Thumbnail.png?VersionId=wvsTjPMZ2PhW5QUtl9QIEj6FIS3xwS4A&itok=TzPo3hwm)
In this TCT 2021 episode of Parallax, Dr Ankur Kalra’s guest is Prof Mamas Mamas, Consultant Interventional Cardiologist at University Hospitals of North Midlands NHS Trust (UHNM), Professor of Cardiology at Keele University and Senior Clinical Editor of TCTmd.
Read More
![Academic Success, Decision-making & Pragmatic Approach](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/EP57_PP_Social_Artwork2_0.png?VersionId=Z.tlaafPFucKKSQY1g6gOM5MfOLlPqI8&itok=kzt1-DFg)
In celebration of Diwali, Dr. Ankur Kalra sat down with Dr. Ambarish Pandey, Assistant Professor at The University of Texas Southwestern Medical School, to talk about his career path and the questions that shaped his decision-making over the years.
Read More
![Parallax HFSA Edition: Diversity, Equity, Inclusion & Belonging with Dr Nancy M. Albert](https://assets.radcliffecardiology.com/s3fs-public/styles/podcast_episode_teaser/public/podcast-episode/2024-02/EP56_PP_Social_Artwork2.png?VersionId=VZ0MM2neqFfUYaGSKTxejSWQQtSYxynC&itok=JfvloKdX)
This week’s Parallax in collaboration with the Heart Failure Society of America (HFSA) explores the many ways organisations can embrace the needs of a diverse community and create a culture that can react to the realities of patientcare.
Read More